The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of ...

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...

(RTTNews) - Roche (RHHBY) announced that the European Commission has approved PiaSky (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5. It is approved for ...

Roche Holding said that the European Commission has approved blood disorder injection PiaSky. The Swiss pharmaceutical giant said Tuesday that the approval follows a Phase III study which showed ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The European Commission (EC) has approved Roche’s recycling monoclonal antibody, PiaSky (crovalimab), for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult and adolescent ...

Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the ...

With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce treatment burden for people with paroxysmal nocturnal haemoglobinuria (PNH) in Europe and their caregivers Approval ...